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Abstract: Paraneoplastic pemphigus is a rare autoimmune disease of the skin associated with neoplasm. Nowadays, the 
pathogenesis of paraneoplastic pemphigus is not fully understood. Due to its rarity, various criteria have been proposed 
for the diagnosis. For this reason, several diagnostic methods have been considered useful for the diagnosis of    
paraneoplastic pemphigus including indirect immunofluorescence, direct immune of fluorescence, immunoprecipitation, 
immunoblotting, and enzyme-linked immunosorbent assay (ELISA). However, the polymorphic clinical features and 
the various results of laboratory tests and pathological evaluation present a challenge for the clinicians. 
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araneoplastic pemphigus (PNP) is a rare autoim-
mune blistering disease of the skin, which was 
first described by Anhalt et al. in 1990[1]. PNP is 
always associated with neoplasm, among which B-cell 
lymphomas and other hematological malignant diseases 
are most common[2]. In 2001, Nguyen et al. suggested the 
term “paraneoplastic autoimmune multiorgan syndrome” 
(PAMS) as several organs are affected and auto-    
antibodies bind several tissues[3]. Due to its high mortal-
ity rate, PNP must be detected quickly[4]. 
Epidemiology 
PNP is a rare disease. Presently, there is limited data on 
the prevalence of PNP. Over 450 cases are described in 
the literature to date[5,6]. PNP usually affects patients 
aged between 45 and 70 years. Ogawa et al. reported that 
the mean age of onset in his series was 64.7[7]. However, 
PNP can affect every age group, including children and 
adolescents[8-10]. PNP appears to affect males and females 
equally[2]. 
Etiology  
PNP is mostly associated with lymphoproliferative dis-
orders[2]. Nearly 84% of all PNP are found in association 
with hematologic neoplasms or disorders[2,6]. Among 
these, non-Hodgkin’s lymphoma accounts for 38.6%, 
chronic lymphocytic leukemia for 18.4%, Castleman’s 
disease for 18.4%, thymoma for 5.5%, Waldenstrom’s 
macroglobulinemia for 1.2%, Hodgkin’s lymphoma for 
0.6%, and monoclonal gammopathy for 0.6%[2,5,6,11]. In 
addition, carcinomas developed from epithelial cells 
(8.6%)[12-14], sarcomas derived from mesenchymal lines 
(6.2%)[9,15,16], and melanoma (0.6%)[17] also are reported 
in association with PNP. There are also cases of PNP 
triggered by cytotoxic drugs[18,19] and radiotherapy[20] 
described in the literature. 
P 
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Genetics 
HLA-DRB1*03 and HLA-Cw*14 are associated with 
PNP in Caucasian[21] and in Chinese patients[22] respec-
tively. The HLA-DRB1*03 and the HLA-Cw*14 alleles 
were found more frequently, respectively in a series of 
13 Caucasian French patients[21] and of 19 Han Chinese 
patients[22] than in the control populations. The Chinese 
patients with PNP did not show HLA-DRB1*03 allele[22]. 
Pathogenesis 
The pathogenesis of PNP is not completely known. On 
one hand, several autoantibodies could play a pivotal role 
in PNP. Autoantibodies directed against the plakin family 
are typically found in PNP, including antibodies against 
the 210 kDa envoplakin, the 190 kDa periplakin, the 250 
and 210 kDa desmoplakins I and II, the 500 kDa plectin, 
and the 230 kDa bullous pemphigoid antigen[23-26]. Fur-
thermore, antibodies against plakophilin 3 and desmo-
collins (DSC) 1–3 have also been detected in some 
studies[27,28]. In addition, autoantibodies against desmo-
glein-1 (DSG-1) and desmoglein-3 (DSG-3) may also 
have pathogenic activity[29,30]. However, Amagai et al. 
reported a positivity of 100% only for anti-DSG-3 
autoantibodies[29]. Recently, the protease inhibitor α2- 
macroglobulin-like-1 (A2ML1) has been considered as 
the possible pathogenic in PNP[31,32]. 
On the other hand, the cell-mediated immunity could 
have a role in PNP[2,33]. Another study reported the pres-
ence of selective epidermal activated CD8+ T-cells in 
PNP[34]. There are also four PNP patients without any 
detectable autoantibodies described by Cummins et al[35]. 
Furthermore, another study showed that MHC-restricted 
CD8+ cytotoxic T lymphocytes, non-MHC-restricted 
CD56+, and CD68+ natural killer cells are at the   
dermo-epidermal junction of PNP lesions[36]. 
Clinical features 
PNP is identified by polymorphous lesions involving the 
skin and different mucosae. The variety of lesions 
could be explained by the presence of different auto- 
antibodies in different patients[2]. Mucosal lesions are 
often the earliest features in PNP[37-39]. Oral mucosa is 
always affected in PNP (Figure 1)[37-40], although one 
PNP case without oral involvement is reported in the 
literature[41]. Usually severe erosions and crusting are 
found on the vermilion of the lips, showing an erythema 
multiforme-like or a Stevens-Johnson-like appearance. 
Erosions also affect the oropharynx, causing a painful 
stomatitis. In addition, mucosal lesion can also involve 
the nasopharynx, conjunctivae, anogenital region, and 
esophagus[6,42,43]. Cutaneous lesions usually rise after the 
onset of mucosal lesions[2,40]. The most involved sites are 
the trunk, head, neck, and proximal extremities, although 
most patients show a widespread cutaneous involvement 
(Figure 2)[4,40,44]. Different kind of lesions may coexist 
and evolve from one type to another[3,40]. Cutaneous le-
sions could be similar to those seen in pemphigus, pem-
phigoid, erythema multiforme or graft versus host 
disease[11,38,40]. Pustular and psoriasis form presentation 
have also been described[3]. The different clinical fea-
tures could be linked to the predominance of the cell- 
mediated or humoral-mediated cytotoxicity[36,38]. It is 
well known that if the principal mechanism is hu-
moral-mediated cytotoxicity, a usual pemphigus appear-
ance might be prominent[3,6]. In contrast, if cell-mediated 
cytotoxicity is the leading mechanism, lichenoid lesions 
might be easily seen[33,35,36]. Lichenoid lesions are com-
monly detected in children, especially on the trunk and 
limbs[9,10]. Lesions resembling those of pemphigoid are 
usually present on the extremities[45]. Sapadin et al. re-
ported a singular case of pemphigus vegetans-like  
 
Figure 1 Painful erosions of the lips 
 
 
Figure 2 Extensive areas of denudation 
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PNP[46]. PNP can also involve the respiratory epithelium 
in 59.1%–92.8% of cases[8,36], causing dyspnea, obstruc-
tive lung disease and bronchiolitis obliterans, which 
may be fatal[6,47]. However, the pulmonary involvement 
affects mainly children and Chinese patients with Cas-
tleman’s disease[40,47]. Usually, a neoplasm is de-
tected before the onset of PNP[4,38–40]. However, in about  
30% of cases PNP, the clinical manifestation leads to the 
detection of an occult tumor[36,38]. 
Histological features 
The pathological findings vary with the clinical features[4,30]. 
On one hand, suprabasal acantholysis with scattered in-
flammatory infiltrates could be detected in presence 
of blisters (Figure 3)[30]. Furthermore, the presence of 
dyskeratosis with suprabasal acantholysis is a clue to 
paraneoplastic pemphigus. On the other hand, interface 
and lichenoid dermatitis are more easily detected in ery-
thematous inflammatory maculopapular lesions[30,35]. 
Lesions with a mixed clinical feature might show con-
comitant acantholysis occurring with lichenoid interface 
dermatitis[30,38,40]. 
 
Figure 3 Histology of a skin biopsy shows suprabasal acan-
tholysis. (H&E, magnification 200×) 
Immunological studies 
Direct immunofluorescence (DIF) usually shows IgG 
and/or C3 deposition in the epidermal intercellular 
spaces (EIS) alone[48]. The deposition of IgG and/or C3 
in EIS and in the basement membrane zone is reported 
to be less than 50% of cases[48]. In addition, linear depo- 
sits of IgG or C3 in the basement membrane zone 
could be detected[30]. This pattern could be a clue to dif-
ferentiate PNP from other forms of pemphigus, in which 
Ig deposits are detected only between keratinocytes[3]. 
However, DIF is found to be negative in approximately 
50% of the cases[48]. False negatives are commonly due 
to necrotic tissue (especially in mucosal biopsies) and the 
lichenoid clinical pattern of some lesions[35,48]. 
Indirect immunofluorescence (IIF) could be perfor-
med on different substrates, including normal human 
skin, rat bladder (Figure 4), rat myocardium, rat lung, 
and monkey esophagus[48]. IIF detects autoantibodies to 
plakins; among them, autoantibodies to envoplakin and 
periplakin are the most specific[30]. IIF on normal human 
skin has been shown to be positive in up to 50% of the 
cases, whereas IIF on rat bladder urothelium has been 
found positive in 75% of the cases, showing a better sen-
sitivity[38,49]. Furthermore, IIF on rat bladder has shown a 
high specificity (83%)[1,49]. For these reasons, IIF on 
rat bladder is now considered a useful screening test for 
PNP. However, autoantibodies directed against members 
of plakin family have been also detected in other condi-
tions including pemphigus vulgaris, pemphigus foliaceus 
and Lyell’s syndrome[49-51]. 
 
Figure 4 Positive indirect immunofluorescence on rat     
urinary bladder epithelium 
 
Enzyme-linked immunosorbent assay (ELISA) can be 
used to detect anti-DSG-3 and anti-DSG-1 autoantibo-
dies in PNP, although most PNP patients have been 
shown only with anti-DSG-3 IgG[52]. However, there 
were also PNP patients without anti-DSG autoantibodies 
described in the literature[52]. In 2009, Probst et al. de-
veloped a new ELISA using a recombinant 56 kDa 
N-terminal fragment of envoplakin which shows a sensi-
tivity of 82% and a specificity of ≥ 98%[53]. Recently, 
Ishii et al. detected IgG autoantibodies to DSC-1, DSC-2 
and DSC-3 in 16.5%, 36.7% and 59.5% of PNP sera res- 
pectively, using a novel mammalian ELISA[54]. 
Immunoprecipitation (IP) has been considered as the 
gold standard for the diagnosis of PNP[55]. IP can show 
antibodies against several epidermal antigens, including 
plakin family and A2ML1[31]. In addition, a positive IP 
test is a major criterion for the diagnosis of PNP[56]. 
Immunoblotting (IB) has been used to detect anti-
bodies against desmoplakin I and II, periplakin, and en-
voplakin on normal human keratinocytes extracts[30,48]. 
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Diagnosis 
According to Anhalt et al., the diagnostic criteria in-
cludes five different points (Table 1)[1]. However, Camisa 
et al. proposed different criteria, including major and 
minor criteria (Table 2)[56]. According to Camisa et al.,  
three major criteria or two major and two minor criteria 
are needed to diagnose PNP[56]. Furthermore, Mimouni et 
al.[9] revised the original criteria proposed by Anhalt et al.[1] 
(Table 3). Nowadays, DIF is considered non-essential for 
diagnosing PNP due to its low sensibility[48,49]. IIF on 
rat bladder urothelium and monkey esophagus are 
thought to be useful as a screening for PNP[36,38,48]. In 
addition, the detection of anti-DSG-3, anti-DSG-1, 
anti-DSC-1, anti-DSC-2 and anti-DSC-3 antibodies by  
 
Table 1 Diagnostic criteria originally proposed by Anhalt et 
al.[1] 
Parameter Criterion 
Clinical features Painful erosions involving mucosae with 
or without a multiform skin eruption 
producing blisters and erosions, occurring 
in association with an occult or evident 
neoplasm 
Histopathology Suprabasal intraepithelial acantholysis, 
vacuolar interface changes and necrosis of 
individual keratinocytes 
Direct 
immunofluorescence 
Combined presence of IgG and 
complement (C3) granular-linear 
deposition within the epidermal 
intercellular spaces and along the 
basement-membrane zone 
Indirect 
immunofluorescence 
Presence of circulating antibodies that 
target the intercellular zone of stratified 
squamous or transitional epithelia 
Immunoprecipitation Typical complex of proteins including 
desmoplakin I (250 kD), bullous 
pemphigoid antigen (230 kD), envoplakin 
(210 kD), desmoplakin II (210 kD), 
periplakin (190 kD) and  α-2- 
macroglobulin-like-1 (170kD) 
 
Table 2 Diagnostic criteria proposed by Camisa et al.[55] 
Relevance Description 
Major Polymorphic clinical features involving the skin 
and mucosae 
Presence of an underlying neoplasia 
Characteristic immunoprecipitation pattern of 
auto-antibodies 
Minor Clear acantholysis on skin biopsy 
Direct immunofluorescence highlighting inter- 
cellular and basement membrane staining 
Positive indirect immunofluorescence on 
rat-bladder epithelium 
Table 3 Diagnostic criteria proposed by Mimouni et al.[9] 
Criterion 
Detection of auto-antibodies against desmoglein 1 and 3, 
envoplakin, periplakin, and plectin 
 
Exclusion of other disease positive to anti-desmoglein 1 and 3 
autoantibodies 
 
Respiratory tract affected by the disease 
 
Lichenoid clinical features on skin 
 
ELISA is useful to formulate a correct diagnosis[57]. Fur-
thermore, the link between anti-DSG-3 antibodies and 
bronchiolitis obliterans (BO)[58] has been reported as one 
of the most important complications of PNP patients. The 
detection of antibodies against A2ML1 using IP and IB is 
also useful for the diagnosis of PNP[31,57]. Indeed, Oh-
zono et al. reported that 60.4% of the patients showed 
positivity for anti-A2ML1 antibodies that was higher 
than the positivity for anti-DSG-1 antibodies[57]. 
In conclusion, as PNP is primarily associated with an-
tibodies against the plakin family, IP is considered as the 
laboratory gold standard for the diagnosis of PNP[55,56]. 
However, rat bladder IIF in combination with IB offers 
an easier and more accurate alternative to IP[59]. Further-
more, the laboratory data should be related to the clinical 
features[38-40]. In addition, it is mandatory to detect the 
underlying malignancy[38-40]. 
Treatment options 
High-dose corticosteroids are used as the first line ther-
apy[60,61]. However, corticosteroids are usually combined 
with other immunosuppressive drugs. Only two papers 
reported an improvement of the lesions using only corti-
costeroids[60,61]. Prednisolone in association with other 
immunosuppressive drugs including azathioprine[1], cyc-
losporine[62], mycophenolate mofetil[63] and cyclophos-
phamide[64,65] have been shown efficient. In addition, the 
combination of prednisolone and intravenous immu-
noglobulins[38-40] or plasmapheresis[66,67] have been repor-
ted effective in selected number of patients. However, 
mucosal lesions are usually resistant to most of the thera-
peutic schedules. 
Rituximab, the anti-CD20 monoclonal antibody, has 
improved the clinical picture in PNP patients with under-
lying B-cell lymphoma[11,68,69]. Alemtuzumab, a human-
ized monoclonal antibody which binds CD52, has 
induced a long-term remission in a patient with B-cell 
chronic lymphocytic leukemia[70]. Daclizumab, a human-
ized monoclonal antibody directed against the alpha 
subunit of the IL-2 receptor of T-cells, is found to be a 
promising drug in treating PNP[38]. 
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On the other hand, whenever feasible, a complete ex-
cision of the benign tumor should be performed. This 
may cause an important improvement of the clinical pic-
ture due to a dramatic reduction of autoantibodies[11,38-40]. 
It has also been suggested to use perioperative intrave-
nous immunoglobulins to block the release of auto-  
antibodies during excision[11]. On the contrary, there is no 
consensus regarding the management of a malignant 
tumor as, in some cases, PNP continues to develop  
despite surgery and chemotherapy[11,38-40]. 
Early antimicrobial therapy is recommended to reduce 
the risk of sepsis due to loss of skin integrity and immu-
nosuppressive therapy[11]. Antalgic therapy is thought 
to be useful in reducing the pain linked to extensive mu-
cosal erosions[11]. 
Prognosis 
The prognosis of PNP is generally poor, with a stagger-
ing 90% mortality rate[4-6,11]. The death is usually 
caused by severe complications including sepsis, gastro-
intestinal bleedings and BO[4-6,11]. At this regard, a 
link between anti-DSG-3 antibodies and BO has been 
reported[58]. Thus, it is important to evaluate accurately 
the respiratory symptoms in patients with a positivity to 
anti-DSG-3 antibodies.  
PNP and underlying malignancy do not have a parallel 
evolution[4-6]. In fact, PNP lesions generally progress 
even if malignancy is removed or under controlled[8-11]. 
However, it has been highlighted that the outcome 
is better in PNP patients with concurrent Castleman’s 
disease or benign thymomas upon removal of the tumor[71]. 
Nevertheless, Dong et al. emphasized that PNP was an 
independent detrimental prognostic factor in Castleman’s 
disease patients which affects the survival rate of these 
patients[72]. 
Conclusion 
Due to its polymorphus clinical appearance, PNP pre-
sents a challenge for the clinicians. Although several 
immunological makers have been discovered, the patho-
genesis remains largely unknown. Different therapies 
have been developed to treat this severe condition as the 
management of the underlying tumor is vital. 
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